Wet age-related macular degeneration

Wet AMD is a progressive eye condition that affects the central vision, causing significant visual impairment. It is characterized by the growth of abnormal blood vessels in the macula, a part of the retina responsible for sharp central vision. These fragile vessels can leak fluid or blood, causing distortion or blurring of vision. Wet AMD typically affects individuals over the age of 60 and can lead to severe vision loss if left untreated.
Medications for Wet AMD:
Anti-VEGF (Vascular Endothelial Growth Factor) Inhibitors: These medications, such as Lucentis (ranibizumab), Eylea (aflibercept), and Beovu (brolucizumab), work by inhibiting the growth of abnormal blood vessels in the macula. They are administered as regular injections into the eye to help slow down vision loss and improve vision in some cases.
Pazopanib: Pazopanib is an oral medication that works by inhibiting the growth of abnormal blood vessels. It is typically prescribed for patients who are not candidates for anti-VEGF injections or have not responded well to them. Pazopanib must be taken under strict medical supervision due to potential side effects.
Patient safety and regular follow-ups are essential when using these medications. Consult with a healthcare professional before starting any treatment to determine the most suitable option based on individual needs and circumstances.